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CNS Tuberculosis in Kerala – A Continuing Challenge with a
Changing Face
Dr.S.R.Chandra and Dr.C.S.Vidhya Annapoorni
ABSTRACT
CNS tuberculosis is a global disease
causing approximately 3 million deaths annually.
In India, 3 million infectious cases, 12 million
non-infectious cases and half million deaths occur
annually. This is likely to increase with
increasing HIV as 50 % of patients with
extrapulmonary TB in USA have HIV making it
a global health problem. Evaluation of patients
with CNS tuberculosis admitted to government
medical college, Trivandarum for one year shows
an interesting picture. It seems to affect
immunocompetent, high socio-economic group
with a long indolent course and leaves significant
complications. Hence we insist the need to
initiate treatment on clinical suspicion only.
Keywords: CNS tuberculosis, immunocompetent
adults.
INTRODUCTION
Tuberculosis is a bacterial disease caused
by airborne droplets of Mycobacterium
tuberculosis, avis and africanum. According to
WHO one-third of world’s population is infected
and approximately nine million new cases and
three million deaths occur worldwide.1 In India,
three million infectious cases, 12 million
non-infectious cases and half million deaths occur
annually.2 Meningitis in patients with
tuberculosis is 7 – 12 % 3. Tuberculosis forms
20 – 30 % of all space occupying lesions. With
the appearance of HIV, there is increased
incidence in the developed countries as well.
Extrapulmonary tuberculosis is considered as an
AIDS defining condition. 5 – 9 % of world’s AIDS
patients have TB and 50% of patients with
extrapulmonary TB are HIV positive in USA.
PATHOGENESIS
Virtually all CNS lesions are produced by
Mycobacterium tuberculosis.4 It is an obligate
aerobic bacillus, non-motile, non-capsulated, and
non-sporing and resembles fungal organisms
forming mould like pellicles in liquid culture.5 Its
genome is the largest among bacteria and has
enzymes for synthesis of complex lipids,
glycolipids, mycolic acid, wax, alcohols etc. These
molecules form a physiological barrier to most
drugs. It has a system for antigenic variation
causing chronicity of disease. It spreads from
person to person by aerosolized droplet nuclei.
One to ten organisms are needed to cause
infection. Severity of disease in the infecting
individual determines severity of disease in the
recipient. It multiplies in the alveoli or
macrophages. Tuberculous exposure occurs in
100% of persons in endemic areas. Most of them
are killed in 2 – 4 weeks. The surviving
organisms hematogenously spread to
extrapulmonary sites. This leads to PPD
reactivity indicating asymptomatic TB infection.
A small percentage of these patients progress to
symptomatic infection. Attempts by mononuclear
cells to control this causes caesation and necrosis,
which breaks and release the organisms in lung
parenchyma. During hematogenous spread
lesions occur in CNS choroids plexus called Rich
focus. They rupture into subarachnoid space
causing meningitis and into parenchyma causing
tuberculoma or abscess. Hypersensitivity reaction
to this causes thick exudates in the basal cisterns
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around vessels and nerves causing proliferative
arachnoditis, vasculitis and hydrocephalus.
Because of these devastating complications it is
called white plague or captain of man’s death.
Damage to brain parenchyma adjacent to areas
of exudates causes borderzone encephalitis and
leucoencephalopathy at distant sites. Other then
the Rich foci, CNS TB occur also from
subependymal, subpial, vertebral, middle ear,
nasopharyngeal and vertebral foci. Based on host
resistances and number of bacilli, spectrum of
clinical presentation varying from focal plaques,
miliary lesions, proliferative meningitis or
inflammatory caseous meningitis occurs.6 Thick
exudates are seen in interpenducular fossa,
infundibulum, optic chiasma, sylvian fissure etc.
Semifibrinous material in between the layers of
leptomeninges, perivascular epitheloid cells,
subintimal thickening of vessels and necrotizing
vasculitis is seen. With introduction of treatment
this becomes organized to fibrous endarteritis
leading to infarctions in 37.5 – 55% of patients.
Obstructive hydrocephalus occurs due to
obliteration of prepontine cisterns whereas
communicating hydrocephalus is due to
leptomeningeal obstruction. Tuberculomas are
commonly found infratentorially among children
and supratentorially in adults6. Spinal
involvement occurs as an extension of cranial
involvement.
CLINICAL FEATURES
Most often illness starts with vague
nonspecific symptoms and low-grade fever of
several weeks. Past history of TB is present in
50% children and 10% adults.6, 7 Cranial
neuropathy is seen in 20-30%. Signs of meningeal
irritation, hemiparesis, quadriparesis, raised
intracranial tension, seizures, movement
disorders followed by lethargy, confusion, stupor
and coma sets in. Mild to moderate hyponatremia
and syndrome of inappropriate ADH secretion are
common. CNS picture is not much altered by HIV
status. Udani and Dastur8 have described
tuberculous encephalopathy in children that
resembles hemorrhagic leucoencephalopathy.
British Medical Research council staging 9
Stage I – prodromal phase with no definite
neurological symptoms
Stage II – mild meningeal irritation and cranial
neuropathy
Stage III – severe clouding of sensorium,
convulsions, focal neurological deficits
Advanced stage of disease, extremes of
age, underlying multiple comorbidities,
hydrocephalus, persistent CSF AFB and culture
positivity are bad prognostic factors.
DIAGNOSIS
Early diagnosis is often difficult due to
lack of specific signs and symptoms. Laboratory
methods are also inadequate.10 CSF shows
lymphocytic pleocytosis with low sugar and raised
proteins. Acute neutrophilic response that shifts
to lymphocytes in 24 – 48 hours is also seen.
Persistent neutrophilia is seen in multidrug
resistant TB (MDR-TB) and mixed infections. A
therapeutic paradox where the initial lymphocytic
CSF shifts to polymorphonuclear after initiation
of treatment is also reported due to massive
release of tuberculoprotein which often ends in
death. AFB stain is positive in 5 – 25 % and
culture positive upto 60%. Approximately 10,000
organisms are required for culture to become
positive which takes 4 – 8 weeks to yield results.
Determination of CSF adenosine deaminase is
seen in all disorders that induce cell mediated
immune response and has 90% sensitivity and
specificity in the diagnosis of tuberculous
meningitis. Diagnostic sensitivity of PCR in CSF
is variable. However evolution from positive to
negative indicates treatment efficacy. TB – color
cold staining is more sensitive method of
microscopic examination of the mycobacterium.
Solid phase enzyme immunoassay is used for the
detection of TB IgG, A, and M; Fast plaque TB
test with application of phage amplification
technology is very sensitive but not easily
available.
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Neuroimaging shows enhancement of basal
cistern and the complications like hydrocephalus,
infarcts and tuberculoma.
OUR OBSERVATION
Patients admitted to Government medical
college hospital, Trivandrum during 2004 March
to 2005 March were evaluated and followed till
2008 December. Twenty-three patients comprised
of nineteen males and four females. Age varied
from eleven years to sixty-two years, 17.8% of
these patients were businessman, 17.8% laborers,
and 17.4% engineers. The rest 47% belonged to
students, doctors and bank officials. The
commonest symptom - fatigue and headache was
seen in all patients. Recurrent superior orbital
fissure (Fig. 1) was seen in two, nasopharyngeal
(Fig. 2 ) lesion in one, extensive and cranio-spinal
tuberculomas (Fig. 3 & 4) in one. Other features
present were pyrexia of unknown origin, seizures,
stupor etc. All of them were immunocompetent.
Delay in initiating treatment varied from 3
weeks to 4 months. There was no mortality.
However only five patients recovered without any
major sequelae. The rest of the patients were left
with varying degrees of cognitive decline, seizures
and focal deficits. The larger the delay in starting
the treatment greater was the sequelae.
TREATMENT
As confirmative diagnosis is not easy and
delay is dangerous, decision to treat is clinical
based on high index of suspicion. The centre for
disease control recommends isoniazid 10-20
mg/kg/day, rifampicin 10-20 mg/kg/day,
pyrazinamide 15-30 mg/kg/day, ethambutol or
streptomycin can be added. Hepatotoxicity should
be monitored every 2 weeks. Duration of
treatment is 6 – 12 months. WHO puts CNS TB
under category I with initial phase for 2 months
with streptomycin, isoniazid, rifampicin and
pyrizinamide followed by 7 months continuation
phase with isoniazid and rifampicin. As
complications in CNS TB are more disabling
most neurologists believe in a conventional
Fig 1. Right orbial granulmatous mass
Fig. 2. Nasopharyngeal tuberculous granuloma
Fig. 3 Multiple tuberculomas in brainstem and spinal
cord
Fig 4. Multiple tuberculomas in brain
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18-month regimen. Indication for steroids are
altered sensorium, focal neurological deficits, CSF
pressure more than 300 mm of water, protein
more than 400 mg/dl, basal exudates and
tuberculomas. Prednisolone 1-3 mg / kg in
children and 60 mg/ day in adults is
recommended. It is reduced to 50% in second
week and tapered gradually over 4 weeks.
Surgery is indicated in the presence of
hydrocephalus.
LESSONS LEARNT
CNS TB in Kerala now seems to be a
disease of immunocompetent, higher
socioeconomic group. Rare presentations like
recurrent superior orbital fissure, nasopharyngeal
and cranial spinal tuberculosis also occur in
immunocompetent individuals. The factors
involved could be stress induced defect in cell
mediated immunity and also frequent use of
quinolones for all kinds of infection leading to
the suppression of symptoms and indolent course.
CONCLUSION
Central system tuberculosis is a
potentially treatable but very dangerous form of
CNS infection. Confirmation of diagnosis is not
easy and clinical suspicion is the indication to
start the treatment. It seems to be common
among the affluent immunocompetent adults
probably due to the effect of wide spread use of
quinolones and life style related stress. It is
better to treat for a longer period of time – 12
to 18 months, with daily drugs when the CNS
is invaded. When resistance to any drug is
suspected susceptibility studies mandate the drug
use.
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Review Article
Newer Insulin and Insulin Pumps
Dr. Jothydev Kesavadev, Ms. Gopikakrishnan Gopalakrishnan,
Ms. Sunitha Jothydev
ABSTRACT
Since the discovery of insulin in 1922 the
ideal route and device for delivery of insulin have
been experimented and studied in several trials.
Although syringes are still popular, insulin pens
have become more acceptable in the last 5 years.
Delivery of insulin with the help of Insulin Pump
described as Continuous Subcutaneous Insulin
Infusion (CSII), though more than 3 decades old
is recently gaining more attention and popularity
because of its multitude of benefits over and
above that of glucose reduction. Insulin Pumps
are a time tested device for continuous
subcutaneous insulin infusion.
Unlike the popular syringes and insulin
pens, insulin pumps will have only regular
human insulin or the rapid acting analogue
insulin in it for both basal and bolus
requirements. There are 4 basal options now
available for the clinician - NPH, glargine,
detemir and CSII. Intrasubject variability is
minimal when rapid acting insulin is used as a
basal with CSII. In India, now majority of
pumpers are using rapid acting analogue insulin
like aspart. When used in Insulin pump, insulin
aspart has proven to produce minimal or no
infusion set blockage compared to insulin lispro.
When rapid acting analogue insulins like aspart,
glulisine etc., are used in pumps, subjects feel
more comfortable and convenient because of its
ease of administration just before the main meals
and snacks. In India, unlike the west, 80% of
the pumpers are Type 2 Diabetes subjects.
Studies published in India have thrown light into
the new findings on dramatic improvement in
peripheral neuropathic pain and improvement in
sexual function when CSII is made use of in the
treatment of Type 2 diabetes. Oral hypoglycemic
agents like metformin and sulfonylureas are
administered along with insulin in pumpers with
type 2 diabetes so that the TDD (Total Daily
Dose) of insulin can be drastically reduced and
at the same time achieve intensive control of
glycemia without the risk of hypoglycemia,
by utilizing the multitude of advanced functions
in pumps. More perfect control of sugars with
minimal excursions is possible with intelligent
use of extra functions like extended bolus,
temporary basal, bolus wizard etc. Whether it is
type 1or type 2 diabetes, periodic CGM
(Continuous Glucose Monitoring) is mandatory to
fine tune the multiple basal profiles and to decide
on diet and exercise pattern. It is intriguing to
realize that the same insulins used in syringes
and pens when incorporated into CSII, subjects
are reporting a profound improvement in QOL
within 3 months of use provided the right
candidate is selected and intensively followed up.
HOW DOES THE PUMP WORK?
Continuous Subcutaneous Insulin Infusion
(CSII) or Insulin Pump Therapy by itself is not
a new therapy for Diabetes mellitus. It is an
alternate delivery mechanism for administration
of insulin and is found to be far superior to
ordinary syringes and insulin pens. When insulin
is administered sub-cutaneously via a properly
programmed insulin pump, physiological delivery
of insulin mimicking a normal healthy pancreas
is achieved.
Modern insulin pumps consist of a small
battery powered device (about the size of a small
cell phone), a disposable reservoir filled with
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insulin and an infusion set, one end of which is
attached to the pump and the other end of which
there is a cannula inserted under the skin, near
the abdomen to deliver insulin to the body. The
pump is programmed in such a way as to the
deliver insulin continuously in tiny doses
throughout the day and night (basal dose in the
range of 0.1-3.0 u/h or more) by using a computer
chip which controls insulin delivery.(2)
HOW THE PUMP EVOLVED?
The history of insulin pump dates back to
1960s when a Los Angeles doctor named Arnold
Kadish introduced insulin pump, a model that
had to be worn as a backpack due to its big size.
Later, the model underwent several clinical tests
before it finally gained recognition as a potential
replacement to regular insulin delivery and in
1978 the first use of CSII was reported by John
Pick up et al(10). Serious side effects such as
ketoacidosis, hypoglycemia, infections and
subsequent mortality caused a setback to the use
of CSII. Pump therapy breathed a new life with
the proclamation of DCCT in 1993 pointing out
CSII to be a significantly better method of
maintaining strict glycemic control in comparison
to other modes of intensified treatment(4).The
importance of tight glycemic control was also
demonstrated by the UKPDS.(8) Since then the
use of CSII gained popularity and there appeared
more user-friendly models with features like
bolus calculators and compatibility with personal
computers so that pumpers could have strict
control on their insulin intake and monitor blood
sugars more effectively.
In 2006 Minimed Medtronic, recognized as
pioneers in insulin pump therapy once again
made history, when they introduced real time
insulin pumps where the glucose sensor and the
pump were combined. Introduction of real time
insulin pumps was a major steppingstone
towards “closing the loop” of insulin delivery,
very near to the dream of inventing fully
automatic devices. Newer pumps are smaller and
easier to operate making it an increasingly
attractive option with added benefits like a
reliable alarm system for malfunction to name a
few.
BENEFITS OF NEW INSULINS
When pumps were introduced 2-3 decades
back, only regular human insulins were in the
scenario. More often buffered human insulins
were used in CSII to make the insulin more
stable for use in the pump. The inherent
limitations of human insulins like crystal
formation, slow onset and prolonged duration of
action, inadequate concentration in the portal
circulation and inappropriate 24 hour basal
serum insulin concentrations leading to poor long
term glycemic control, paved the way for
analogue insulins to hit the pump market.
There exist no arguments on the use of
rapid acting insulin analogs in insulin pump
therapy. Studies have shown that absorption of
soluble, short-acting insulins used in CSII varies
by less than 3% daily (2) when compared to basal
insulins which vary from 19% to 55% in the same
individual, which accounts for blood glucose
variability when syringes or pens are used as
delivery devices. Rapid acting insulins can be
administered just before or even soon after food
resulting in improved compliance and better
quality of life for subjects on CSII. Tiny doses
can also be administered along with snacks
without poking the skin. In our center we have
never come across pump blockage in more than
110 subjects on insulin aspart in the pumps.
Insulin aspart is the preferred insulin analogue
for use in CSII due to improved glycemic control,
lower post prandial peaks, lesser risk of
hypoglycemia, decreased glycosylated hemoglobin,
fewer pump-tubing occlusions and improved
quality of life(13).
An added benefit of using aspart in CSII
is that it causes no weight gain as opposed to
the same insulin when used in MDI regimen (14).
Insulin glulisine is also found to be suitable for
use in pumps. Insulin lispro have been reported
to cause erratic and unpredictable glucose
fluctuations because of precipitation in infusion
catheters (11,12).
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INSULIN STACKING AND BOLUS WIZARD
When new rapid acting analogue insulins
are used in pump, 1800 rule is made use of in
calculating the Insulin Sensitivity Factor. This
takes into consideration the Total Daily Dose
(TDD) of insulin, a sum of both basal and bolus.
Eg.for a patient taking 40 units (TDD) of insulin
aspart daily, ISF = 1800/40= 45 and therefore 1
unit of aspart in this subject will help reduce
blood glucose by 45 mg%. Modern insulin pumps
will help program the different ISFs at different
times of day and night based on the diurnal
changes in insulin sensitivity.
Smart insulin pumps take into
consideration the phenomenon of “active insulin”
which is the bolus insulin which is active from
a previously administered bolus (Bolus on Board
or BOB) so that when the subject is using the
Wizard function for administering bolus, the
active insulin is subtracted with total avoidance
of hypoglycemia.
ADVANTAGES OF CSII
CSII provides opportunity for setting
several basal rates thus allowing flexibility in
dosing. Extra boluses can also be administered
at the will of the patient before, after or during
a meal(16). Earlier studies have shown that most
poorly controlled subjects on MDI achieved a
significant improvement in control after changing
over to insulin pump therapy (10). The following
improvements can be reasonably expected
following initiation of pump therapy.
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As early as 1980s, the benefits of using
an insulin pump in patients in a hospital setting
were published from India.(15) Recent scientific
evidence supporting the use of insulin pumps in
T2DM points to not only significant reduction in
glycated hemoglobin levels but also to improved
quality of life. In a real life study conducted in
our center, a total of 46 subjects with
T2DM using MDI were switched over to CSII for
6 months. HbA1c, body weight and total daily
dose of insulin were measured before initiation
of CSII and compared with the values 6 months
later. After 6 months of CSII, study subjects were
asked about their satisfaction with the therapy;
they were also asked to assess treatment
flexibility, frequency of side effects and
interference with regard to side effects. The mean
HbA1c value 6 months after initiation of CSII
was 7.6 ± 1.2%, compared to 8.1 ± 1.4% at
baseline while using MDI. The difference in mean
between the 2 groups (0.541) was statistically
significant and subjects also expressed high
overall satisfaction level with CSII after 6
months.(1)
 Subjects were also asked to assess how
CSII affected the sexual function and peripheral
neuropathic pain. After 6 months of CSII 83%
of subjects noted an improvement in sexual
function as opposed to when they were using
MDI. With respect to peripheral neuropathic
pain, 87% of subjects reported that they
experienced significant reduction in pain after
initiation of CSII.(1)
In a retrospective analysis of the medical
records of 43 patients who were initiated on
Insulin pump therapy between 2002 and 2007
(Dr.V.Mohan et al), 33 patients, 17 with type1
diabetes and 16 with type 2 diabetes who were
on CSII were followed up for a mean duration
of 3.4 years. The study aimed at evaluating the
safety and effectiveness of CSII among
“Recalcitrant Diabetes” showed a statistically
significant reduction in HbA1c after initiating
CSII (prepump 10.7% vs.postpump 8.3%,
p<0.001) and there also occurred a reduction in
frequency of severe hypoglycemia after starting
the CSII with no instances of diabetic
ketoacidosis. The greatest reduction in HbA1c
levels occurred in the first 6 months with a slight
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deterioration thereafter possibly because some
patients “relaxed” the control after the initial
success with pumps was achieved.(3)
In insulin requiring T2DM, a judicious use
of insulin pumps in selected candidates is not
only beneficial in reducing glycated hemoglobin
(HbA1c) levels, but also in minimizing glycemic
excursions(5). More recent studies with insulin
pumps have shown excellent improvement in
quality of life, sexual function and symptoms of
peripheral neuropathy.
A case report was presented at the
American Diabetes Association (ADA) meeting
in 2007 of a 58 year old subject with T2DM of
20 years duration with bilateral peripheral
painful neuropathy. Insulin pump therapy
resulted in dramatic improvement in neuropathic
symptoms. By the sixth day of pump deployment
definite signs of improvement were revealed
without any concomitant medications for
neuropathy and by the tenth day the pain almost
disappeared which had most responded to
multiple daily insulin shots. The relief of pain
remained consistent resulting in incredible
improvement in the quality of life.(6)
INDICATIONS FOR INSULIN PUMP
THERAPY
T1DM
Insulin Pump Therapy is a fully
established insulin delivery option in T1DM. In
the scenario where virtually no insulin is being
produced from pancreas, pumps offer near
physiological delivery of insulin and are a proven
time tested therapeutic option in T1DM at all
ages. Any subject with an established diagnosis
of T1DM is a potential candidate for pump
provided other inclusion criteria are fulfilled.
T2DM
T2DM is characterized by progressive beta
cell dysfunction in the presence of insulin
resistance. Eventually the insulin secretory defect
predominates, resulting in an insulin-requiring
state. As opposed to insulin resistance, which
tends to plateau, beta cell dysfunction progresses
over time. Thus people with T2DM eventually
require insulin therapy to maintain glycemic
control, in addition to their oral antidiabetic
agents (9).
In insulin requiring T2DM, a judicious use
of insulin pumps in selected candidates is not
only beneficial in reducing glycated hemoglobin
(HbA1c) levels, but also in minimizing glycemic
excursions. More recent studies with insulin
pumps in T2DM have shown excellent
improvement in quality of life, sexual function
and symptoms of peripheral neuropathy (5).
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INSULIN PUMPS IN BODY WEIGHT
REDUCTION
Weight gain with insulin therapy is a
major concern, during the course of diabetes
treatment. This phenomenon is more of a
consequence of treatment rather than property of
insulin. When insulin pumps are used insulin
delivery can be adjusted based on carbohydrate
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content of the diet, exercise type and duration,
time of the meal etc etc. Intelligent and timely
use of pump functions like temporary basal,
extended bolus etc prevents hypoglycemia and
overeating. This invariably leads on to glycemic
reduction without the associated hazard of weight
gaining.
The property of the pump to deliver tiny
boluses can be made use of snacks which
precludes overuse of insulin resultant low sugars,
overeating and weight gain. However studies
have shown(1,14) weight reduction with use of
insulin pumps only when subjects are judiciously
using it, utilizing atleast the basic functions
combined with a structured exercise pattern.
VALUE OF CONTINUOUS GLUCOSE
MONITORING (CGM)
Continuous Glucose Monitoring system
should be regarded as the next revolution in
glucose monitoring and thereby in the day to day
management of diabetes. CGM is advocated for
monitoring blood glucose continuously over a
period of three to six days or more whereby
which 288 blood glucose readings are obtained
in a single day over an interval of 5 minutes.
CGM presents data on blood sugar pattern which
can never be obtained with the help of blood
sugar meters. CGM is similar to a video
providing blood glucose pattern over several days
whereas self monitoring of blood glucose can only
provide values similar to that of a picture which
is less descriptive. Continuous glucose monitoring
devices are being marketed by several
manufacturers nowadays. The Paradigm Real
Time Insulin pumps from Minimed Medtronic are
also available now along with Continuous
Glucose Sensing technology and this is called
Real Time Paradigm Insulin pump and it offers
the added advantage of predictive alerts. The
data that has been gathered from CGM has
enabled us to learn more about the phenomenon
of glycemic excursions, to redefine the so called
normal sugars in entities like Gestational
Diabetes Mellitus, to decide on the basal profiles
in patients on Continuous Subcutaneous Insulin
Infusion etc. The CGM data has also helped the
scientific community to establish the intimate
link between diabetes and cardiovascular
illnesses from a different dimension. Excessive
oxidative stress due to hyperglycemia and
glycoxidation leads to increased production of F2-
isoprostane and eventually 8-iso- PGF2 alpha.
This in turn will lead on to higher platelet
activation which is reflected upon by an
increased urinary excretion of platelet derived
TxB2 and this will result in the higher levels of
plasminogen activator inhibitor (PAI-1) levels.
The glucose trends as studied from CGM data
offers one explanation for the higher
cardiovascular events in diabetes.
In an on original study presented at ADA
2009, we proved CGM,an invaluable tool for fine
tuning sugars in motivated subjects enabling
them to restructure lifestyle based on glycemic
pattern and without any modification in
medications.(7) In our center, 10 highly motivated
subjects on insulin pumps(Minimed
Paradigm),who had training on diet and self
management techniques and on regular
DTMS(Diabetes Tele Management System)follow
up underwent CGM for 3 days. Subjects were
advised to learn by themselves glycemic pattern
and possible cause for fluctuations like diet,
exercise, stress etc. No significant modification in
dosages was carried out afterwards; but reported
their sugars & quality of life improved
significantly in subsequent weeks. This generated
profound interest and prompted us to go for a
qualitative inquiry based on patient interview. A
semi structured interview with open ended
questions on lifestyle depicted their self
modulated response to diet, exercise pattern,
relaxation technique, appreciation of CGM during
sleep & intimate activities. The qualitative
analysis of interview excerpts generated 8 key
themes and frequency of each theme in the group
was captured. Unlike glucometer, CGM helped
in-depth analysis of glycemic pattern which
inspired them to go for diet and lifestyle
modifications assisted with timely advice from
DTMS team. Diabetics in general are scared of
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hypoglycemia during sleep which again got
benefited with CGM.Subjects could appreciate
role of stress in glycemic excursions. A significant
number opted for periodic CGM.These results
strongly indicates utility of CGM in motivated
subjects as a therapeutic tool enabling them to
restructure lifestyles based on glycemic patterns.
CONCLUSION
The new generation insulin pumps and the
newer evidences of benefits, over and above that
of lowering glycated hemoglobin, promise its
extensive use in revolutionizing treatment of
diabetes.
Rapid acting analogue insulins with short
duration of action combined with extra functions
in an insulin pump, when used in the right
candidate, results in profound improvement in
quality of life, diminution of pain of neuropathy
and remarkable improvement in sexual function.
The major disadvantages at present are
the prohibitatively high cost, requirement of
intensive education on a prolonged and
continuous basis and selecting the ideal
candidate who can use it with optimal efficacy.
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Dermatology
Psoriasis - A newly defined systemic disease
Jayakar Thomas, Ashok Kumar N, Manoharan D, Cynthia S, Selva Prabu SK, Ashwak Ahmed.
ABSTRACT
Objective: To study the association of psoriasis
with various comorbid conditions.
Methods: One hundred and twenty consecutive
patients with psoriasis were included in the
study. Complete physical examination was done.
Blood pressure monitoring was done in all
patients. Blood sugar (fasting), fasting lipid
profile and thyroid function test were done in all
patients.
Results: Diabetes mellitus was seen in 11.6% of
patients. Hypertension was present in 14.1%.
Both diabetes and hypertension was seen in
12.5% of patients. 6.6% of patients were obese.
Thyroid disorder and ischemic heart disease were
seen in 3.3% of the patients. Lipid abnormalities
were seen in 4.1% of patients. A total of 55.8%
of patients had some comorbidity in our study.
Conclusion: All patients with psoriasis should
be monitored for associated comorbid conditions.
This study highlights the importance of psoriasis
as a newly emerging systemic disease with
associated co morbid conditions and the role of
dermatologist and physicians in the effective
management of psoriasis.
Key words: psoriasis, co morbid conditions
INTRODUCTION:
Psoriasis is newly defined as a systemic
disease. Common co-morbidities associated with
psoriasis include diabetes, hypertension, and
metabolic syndromes. Psoriasis can have a
significant impact on a patient’s quality of life
and is associated with loss of productivity,
depression, and an increased prevalence of
malignancy1. Pro-inflammatory cytokines such as
tumour necrosis factor-alpha (TNF-alpha), and
other factors like pro-inflammatory T- helper type
I cytokines that are overproduced in patients
with psoriasis likely contributes to the increased
risk for development of metabolic syndrome2. In
terms of the other diseases associated with
psoriasis, Crohn’s disease is another condition
that is not common but its prevalence is certainly
increased in patients with psoriasis3. Depression
or anxiety is another common problem in
patients with psoriasis as is genitourinary
disease. 20 % of hospitalised patients with
psoriasis have some genitourinary complaints.
Patients should adopt a healthy lifestyle so as
not to contribute any more to risk factors.
Treating psoriasis and the associated co-morbid
conditions aggressively from the beginning will
definitely improve the quality of life of the
patient.
PATIENTS AND METHODS:
The study was conducted in the
department of Skin and STD, Sree Balaji Medical
1. Jayakar Thomas,  Professor & HOD, 
Institution- Dept of Skin and STD, 
Sree Balaji Medical College and Hospital
2. Ashok Kumar N, Assistant Professor
Institution- Dept of Skin and STD,
Sree Balaji Medical College and Hospital.
3. Manoharan D, Associate Professor
Institution- Dept of Skin and STD,
Sree Balaji Medical College and Hospital.
4. Cynthia S, Assistant Professor
Institution- Dept of Skin and STD,
Sree Balaji Medical College and Hospital.
5. Selva Prabu SK, Assistant Professor
Institution- Dept of Skin and STD,
Sree Balaji Medical College and Hospital.
6. Ashwak Ahmed, Post graduate
Institution- Dept of Skin and STD,
Sree Balaji Medical College and Hospital
Address for correspondence 
jayakarthomas@gmail.com
135, East Mada Church Road
Royapuram, Chennai.600013. INDIA
TAPI Journal Vol 2, Issue 2, May - August 2010
12
College from April 2009 to December 2009. One
hundred and twenty consecutive patients with
psoriasis were included in the study. All types
of psoriasis patients were included. Complete
physical examination was done. Blood pressure
monitoring was done in all patients. Blood sugar
(fasting), fasting lipid profile and thyroid function
test were done in all patients. Patients with
recent blood reports were not subjected to further
investigation.
RESULTS:
Total of 120 patients were included in the
study. Forty six patients (38.3%) had
Palmo-plantar type followed by chronic plaque
type psoriasis in 50% of patients. Most common
age group was in the range of 41-50 yrs (29%)
followed by 51-60 yrs (27%). 55 % of patients had
the disease for a period ranging from 1-5 yrs.
Diabetes mellitus was seen in11.6% of patients.
Hypertension was present in 14.1%. Both
diabetes and hypertension was seen in 12.5% of
patients. 6.6% of patients were obese. Thyroid
disorder and ischemic heart disease were seen in
3.3% of the patients. Lipid abnormalities were
seen in 4.1% of patients. A total of 67 (55.8%)
of patients had some co-morbidity in our study.
[chart:1]
DISCUSSION:
Psoriasis is emerging as an important
systemic disease associated with various co
morbid conditions. Various co morbid conditions
associated with psoriasis include diabetes,
hypertension, thyroid abnormalities and
abnormal lipid abnormalities. Co-morbid
conditions linked with psoriasis are associated
with increasing rates of morbidity and
mortality.4Besides psoriatic arthritis, other
diseases such as metabolic syndrome and
cardiovascular diseases are becoming of major
importance. The relationship between psoriasis
and co morbidities such is likely linked to the
underlying chronic inflammatory nature of
psoriasis5. Tumour necrosis factor-alpha plays a
central role in the pathogenesis of psoriasis. It
plays a critical role in activation of innate and
acquired immune responses leading to chronic
inflammation, tissue damage and keratinocyte
proliferation. TNF-a levels are markedly
increased in skin lesions, synovium and serum
of patients with psoriasis and these correlate
with the severity of the disease. Decreased levels
are associated with clinical resolution.2 
In a survey on psoriasis patients
hospitalized for treatment, Henseler T and
Christophers E6 investigated a list of concurrent
disorders, both cutaneous and non-cutaneous and
a significant proportion of these patients had
obesity, cardiac disease, hypertension and/or
diabetes. In a study by Sommer DM et al 7,
psoriasis patients are likely to be at risk for the
development of signs of obesity, hypertension and
diabetes, as well as dyslipidaemia and chronic
heart disease. Mallbris et al8 compared rates of
cardiovascular mortality in patients who were
admitted one or more times for psoriasis
treatment with an outpatient cohort and found
that the mortality ratio was 50% higher in
inpatients than in the outpatient cohort.
Although further data are needed it now
seems mandatory to closely monitor psoriasis
patients with a focus on risk factors, including
body weight, hypertension and hyperlipidaemia,
in addition to chronic heart disease. It also
appears necessary to adopt treatment regimens
that not only provide early clearing of the
involved skin but also provide persistently low
inflammatory activity. For effective management
of psoriasis and related co-morbidities, an
integrated approach targeting both cutaneous
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and systemic inflammation may be beneficial,
and strategies to improve overall management of
the patient should be encouraged to reduce the
disease burden.9
Genetic markers 10,11 in future will tell us
who are at risk of developing co-morbidities and
we will be able to intervene earlier and much
more aggressively to prevent premature death.
This study highlights the importance of
psoriasis as a newly emerging systemic disease
with associated co morbid conditions, role of
dermatologist and physicians in the effective
management and drawing up an effective
treatment plan.12.
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Original Article
Microbial Prevalence and their Antibiotic Susceptibility Pattern in
Diabetic Infections
V. Mohan., K. Saritha.,T. Palaniappan., R. Vasudevan
Diabetic individuals have decreased
immunity levels and hence are highly susceptible
to infections (1,2). The relation between diabetes
and infection is synergistic and they form a
vicious cycle by perpetuating each other. Infection
in diabetes can be severe, prolonged and
resistant to treatment and is marked by defective
granulocyte, leukocyte and macrophage function
(3 - 6). The presence of infection can cause
worsening of hyperglycemia or even precipitate
ketoacidosis in some cases.
Diabetic patients are prone to develop a
wide range of infections which include
respiratory, gastrointestinal, urinary tract (7) and
skin and soft tissue infections (8). However, the
most common reason for hospitalization among
diabetic individuals, in India, which also accounts
for a major economic burden (9) at both
individual as well as community level, is diabetic
foot infection. In this paper we report on a ‘real
life’ experience of the pattern of infections in
diabetic subjects as seen at a tertiary diabetic
centre in Chennai.
METHODS:
We conducted a 6-month retrospective
analysis of 474 diabetic inpatients admitted at
Dr. Mohan’s Diabetes Specialties Centre,
Gopalapuram during the period of January 2009
to June 2009. We studied the type of micro
organisms causing infection in diabetic patients.
The study population included 185 male and 289
female patients aged between 15-89 years with
either type 1 or type 2 diabetes. A total of 551
samples were studied which included pus, urine,
blood and tissue from diabetic wounds.
Microorganisms were isolated from clinical
specimens using standard culture methods.
Isolation was done by plating samples on
MacConkey agar & sheep blood agar. Isolated
colonies were processed based on their Gram
stain property.
RESULTS:
The results showed that E.coli was the
commonest organism which accounted to 46.1%
of the total isolates, followed by Enterococcus
faecalis (19.24%) as shown below in Figure 1.
Looking at the pus cultures alone, the
predominant microbe isolated turned out to be
Staphylococcus aureus, which constituted 39 % of
the total isolates followed by Enterococcus
faecalis (19%), E.coli (13%) and Pseudomonas
aerugenosa (9%) respectively as shown in Figure
2. There was not a single isolate of MRSA found
during this study period.
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We next looked at the microbial prevalence
in relation to the glycated hemoglobin (HbA1c)
levels. Figure 3 shows an increasing prevalence
of staphylococcal infection as the HbA1c increases
above 10%.
We also studied the sensitivity pattern of
various antibiotics towards the different
microorganisms isolated. Antibiotic susceptibility
testing was done on Muller Hinton agar with
antibiotic discs by Kirby-Bauer disc diffusion
method. The resistance levels were correlated by
determining the size of zone inhibition for each
antibiotic tested. The sensitivity reports were
analyzed and the results are depicted in Figure
4. The antibiotic sensitivity pattern of individual
microorganism towards each antibiotic tested is
shown as percentage values in Table 1.
Figure 1 : Diagram showing the overall prevalence of microorganisms
6% 6% 8%
9%
13%
19%
39%
Figure 2 : Microbial prevalence in pus samples
Figure 3 : Prevalence of staphylococcal infection in relation to HbA1c
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AMIKACIN 8.4 0.5 4.5 1.2 8.6
AMOXYCILLIN 20.5 1.3
AMOXYCLAV 32.5 3.8
AZITHROMYCIN 2.9
CEFDINIR 0.2 0.5
CEFIXIME 0.6 6.3
CEFOPEROZONE-SULBACTUM 8.2 13.6 3.6 12.5 25.0 6.9
CEFOTAXIME 3.8 4.5 6.0 16.7 12.5
CEFOZOLIN 1.9 4.5
CEFTAZIDIME 1.0 4.5 1.2 16.7 1.7
CEFTIZOXIME 5.8 9.1 6.0 8.3 6.3 12.5
CEFTRIAXONE 6.2 9.1 4.8 33.3 18.8 12.5 1.7
CEFUROXIME 0.6 4.3 1.2 14.1
CEPHALEXIN 1.0 0.6
CIPROFLOXACIN 4.2 3.4 15.5 8.3 6.3 25.9 50.0 2.6
CLINDAMYCIN 3.4 14.7
CO-TRIMOXAZOLE 0.2 2.4 1.3
Figure 4 : Antibiotic sensitivity pattern
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ERTAPENEM 16.6 9.1 11.9 6.3
ERYTHROMYCIN 0.2 3.8 3.2
GENTAMYCIN 3.6 4.5 3.6 3.1 1.7
IMIPENEM 33.3 31.5 27.3 16.7 8.3 21.9 12.5 15.5
LINCOMYCIN 0.6
LINEZOLID 15.2 28.8
MEROPENEM 50.0 2.8 4.5 13.1 3.1 25.0 10.3
NORFLOXACIN 1.8 7.1 8.3 3.1 12.5 12.1 , 
OFLOXACIN 1.0 1.4 9.1 4.8 3.4 50.0 3.2
PERCIN 16.7 2.0 3.6 12.1 , 
PIPERACILLIN 3.4 0.6
TETRACYCLINE 2.9 19.9
TIGECYCLINE 1.2 0.6
Gram-positive organisms like
Staphylococcus (Figure 5) and Enterococcus
showed high sensitivity to drugs like linezolid,
clindamycin, amoxicillin and tetracycline. Among
the gram-negative organisms, majority of them
showed high sensitivity to carbepenems, with
E.coli (Figure 6) showing the highest sensitivity.
Pseudomonas showed highest sensitivity rates to
fluoroquinolone group followed by the
carbepenem group. 
DISCUSSION:
The results of the present study showed
that E.coli was overall the commonest organism
isolated while Staphylococcus aureus was the
commonest organism isolated from pus samples.
In an earlier study conducted at our centre in
2007 (10), the most frequent bacterial isolates
from pus samples were Pseudomonas aeruginosa.
We also found that as the HbA1c (11)
increases, the prevalence of Staphylococcal
infection also increased. The positive correlation
with higher HbA1c values shows that more
severe infection is associated with staphylococcus
aureus infection. Increased glycemic levels and
Figure 5 : Staphylococcus aureus 
Figure 6 : E.Coli
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thereby increased HbA1c values are associated
with a greater risk of foot infections in
susceptible individuals. Staphylococcus aureus is
commonly isolated from purulent discharge of
diabetic foot ulcers and thus seems to be
positively associated with higher HbA1c values.
The exact reason behind this is to be further
elucidated.
We also compared the antibiotic
susceptibility patterns of different micro
organisms studied against the previous results.
Since MIC determination is not done on a routine
basis at our center and in view of the increasing
vancomycin creep (12) and hetero VISA (13) in
the recent times we have not tested susceptibility
to vancomycin. According to the earlier analysis
conducted at our center (10),
Cefoperazone-sulbactam, exhibited high
sensitivity towards gram negative organisms like
Proteus, E.coli and Klebsiella, but now it seemed
to be moderately sensitive against them.
Likewise, Pseudomonas exhibited high sensitivity
to piperacillin, amikacin and imipenem according
to the previous study results (10) but now the
most sensitive was fluoroquinolone group
followed by the carbepenems.
This shows that microbial sensitivity
pattern to antibiotics keeps changing over time.
Hence it is very important to form an antibiotic
policy according to the prevalent organisms in
each institution rather than strictly following the
routine guidelines. Selection of the antibiotic
should be empirical according to the existing
sepsis guidelines and available gram stain or
culture data in the first 24 hours. We can later
alter the antibiotic regimen on the basis of the
available data. Treatment plan should thus be
tailored according to the clinical and
microbiological profile of each patient.
This study also shows that both antibiotic
therapy and good glycemic control are important
in the treatment of infection in a patient with
diabetes. It has been well documented that
improper selection and inappropriate overuse of
antibiotics is more often responsible for the
emergence of resistance and thereby failure of
antimicrobial therapy (14 -16). Hence it is
recommended that the antibiotic choice should be
made after taking into account factors like,
pharmacoeconomics, Pk / Pd properties,
prevalence of MDR strains and the antibiotic
resistance patterns prevailing in that particular
centre / region. Local susceptibility data should
always be kept in mind. Indeed data from one
centre in an area may be useful to other centres
in that region.
Though there is ample clinical data
supporting the role of hyperglycemia in
increasing the risk of serious infections, a study
done by Van den Berghe et al (17) demonstrated
a significant decrease in mortality in patients,
who received intensive insulin treatment (blood
sugars between 80-110mg/dl), while in ICU. The
role of good glycemic control in minimizing
postoperative infections is also well supported
(18,19).
To summarize, studies done at a three to
six months interval, to analyze the pattern of
microbial infections and change in their antibiotic
susceptibility should be considered at an
institutional level and this along with optimized
antibiotic usage and good diabetes control
certainly helps in achieving better outcomes in
the management of diabetic infections. Every
institution must have an antibiotic policy and
stewardship (20,21). Patients with certain
infections must be quarantined. The use of
certain higher antibiotics on a routine basis in
the general wards must be curtailed and they
should be used only by the concurrence of two
treating physicians in order to prevent the
emergence of antibiotic resistance.
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Epidemiology
Intra Urban differences and Double Burden of Under Weight and
Over Weight in Developing World
Dr. Vijay Viswanathan., Dr. Shabana Tharkar
Urbanization is on rise and so is urban
poverty in the developing nations. Even though
there is evidence of 21st century epidemiologic
transition, the constant fear of malnourishment
cannot be evaded. The paradox of overweight and
underweight is continuing to haunt the public
health professionals and policy makers.
The double burden of underweight and
overweight in a developing country is an issue
which is being addressed lopsidedly. The WHO
Collaborating centre for research, education and
training in diabetes has generated substantial
evidence on growing disparities of weight among
the two populations – slums and the higher elite
group within the same geographic region in city
of Chennai. The survey conducted in 2008,
showed huge intra urban differences in the
age-wise mean weight between the two groups
of populations as shown in figure 1 and 2 for
boys and girls respectively. Data on mean weight
is available for the general population upto 80
years and the disparity between the two groups
exists at all ages and the gap between under
nutrition and over nutrition continues to widen.
Economic growth, affordability and easy
Dr. Vijay Viswanathan and Dr. Shabana Tharkar
MV Hospital for Diabetes and Diabetes Research
Centre
WHO Collaborating Centre for Research, Education
and Training in Diabetes
No-4, Main Road, Royapuram, Chennai – 13.
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Figure – 1 Comparison of age-wise mean weight in kgs for boys between high socio economic (HSES) status and
slum dwellers (LSES)
On comparison with WHO standards- Weight for Age Boys:
Z Scores (8 to 10 years)
(Age in years –Weight in Kgs)
8 - 25.4; 9 - 28.1; 10 - 31.2
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availability of calorie rich food are the causes of
over nutrition among higher socio economic group
while poverty, unemployment and unaffordability
are the causes for underweight and under
nourishment among slum dwellers. Hence, both
non communicable diseases and obesity related
conditions like heart disease, stroke, diabetes and
cancer which are lifestyle disorders and
communicable diseases, infections are on a
parallel rise in low and middle income countries.
Despite the WHO Global strategies on
health promotion and chronic disease prevention,
an increasing trend exists among the non
communicable diseases. Hence the healthcare
system must fight from two different fronts.
Strategies must be developed with comprehensive
planning and multi - sectoral approach to
optimize the malnutrition and weight – reduction
of obesity (over nutrition) among high
socioeconomic status and improvement of under
nutrition among the under privileged society. A
framework of guidelines must be formed
exclusively for developing countries to combat the
nutrition related diseases and disorders. In
countries like India, where the public health
system is not very well developed, a
public-private partnership is solicited to work
towards the common goal of health promotion,
disease prevention and the right for health for
every human.
Views and suggestions are welcomed by
leading physicians, researchers and policy makers
from developing world to plan strategies to
confront this issue of double burden.
Figure – 2 Comparison of age-wise mean weight in kgs for girls between high socio economic status and slum
dwellers
On comparison with WHO standards- Weight for Age Girls:
Z Scores (8 to 10 years)
(Age in years –Weight in Kgs)
8 - 25.0; 9 - 28.2; 10 - 31.9
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Toxicology
Toxicology clinics – bench to bed side:
Oximes in OP poisoning - Absolute or Obsolete?
Dr.S.SenthilKumaran, Dr.N.Balamurgan, Dr.V.Karthikeyan
Organophosphate (OP) poisoning is
prevalent in agricultural communities and has
reached an epidemic proportion in the developing
world. Clinical features of acute poisoning can be
rapid or delayed depending on the nature of the
compound and the route of exposure. OP
pesticides inhibit acetyl cholinesterase (AChE) at
the muscarinic and nicotinic synapses by
depositing a phosphoryl group at the enzyme’s
active site, thus resulting in accumulation of
acetylcholine and uncontrolled activation of
cholinergic synapses. Standard therapy attempts
to reduce absorption by gastric lavage and oral
administration of activated charcoal, as well as
administration of atropine and oximes to counter
the effects of absorbed pesticide. Though the use
of atropine is well established, the use of oxime
is debatable. 
What are the available oximes?
Pralidoxime, Obidoxime, Hl6, and Hlo7 are
the available oximes across the globe. Among all
oximes obidoxime is the most potent. Pralidoxime
is the commonly available oxime in India. It is
very expensive, but less potent.
What is P2AM?
It is nothing but pralidoxime chloride.
Pralidoxime occurs in three forms - chloride,
iodide and sulphate. Among all three, chloride
form, is about 1.5 times more potent than the
iodide salt. It mainly acts on the peripheral
nervous system because of its poor lipid solubility
and restricted entry into the CNS. The main
therapeutic effect of pralidoxime is expected to
be recovery of neuromuscular transmission at
nicotinic synapses.
How do oximes work?
These oximes cleave covalently bound OP
off the OP-acetyl cholinesterase (AChE) complex;
thereby reactivate acetyl cholinesterase by
removing the phosphoryl group. In vitro
experiments have shown that oximes are effective
reactivators of human AChE inhibited by OP
compounds. This pharmacological effect of oximes
has not translated, in oxime trials in human OP
poisoning, to improvements in clinical outcomes.
How do oximes work?
These oximes cleave covalently bound OP
off the OP-acetyl cholinesterase (AChE) complex;
thereby reactivate acetyl cholinesterase by
removing the phosphoryl group. In vitro
experiments have shown that oximes are effective
reactivators of human AChE inhibited by OP
compounds. This pharmacological effect of oximes
has not translated, in oxime trials in human OP
poisoning, to improvements in clinical outcomes.
Why oximes are ineffective in human?
I Poor affinity for the particular
OP-AChE complex
Most OP pesticides can be classified as
compounds that form either a
dimethylphosphoryl or a
dimethylphosphoryl-AChE complex. Diethyl
compounds both reactivate and age significantly
slower than dimethyl compounds.
II Persistence of the OP within the
patient and therefore rapid re inhibition
of newly reactivated enzyme,
III Ageing of the inhibited AChE
In the inactive state, AChE is prone to
“aging,” a process by which one alkyl side chain
of the phosphoryl moiety is removed
Corresponding author:
Dr.S.SenthilKumaran, MD, Dip A&E,
Department of Emergency & Critical Care medicine,
Sri Gokulam Hospitals, Salem.
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nonenzymatically, leaving a hydroxyl group in its
place. Once AChE is “aged,” regeneration is not
possible. The therapeutic window for oximes is,
therefore, very much determined by the rate of
ageing.
What are the complications of oximes?
Complications of oximes reported in
literature include hypertension, dysrhythmias,
cardiac asystole, headache, blurred vision,
dizziness, methemoglobin and muscle weakness.
Why there are controversies?
In the current scientific milieu, practice in
medicine is largely evidence based. When we look
at the issue of oxime therapy in humans, the
recommendations are largely based on animal
data. In vitro studies in animals and on human
erythrocytes have suggested beneficial effects of
oximes on reactivating AChE. However, clinical
experience in the developing world has
questioned the relevance of oximes for any form
of OP poisoning. Senanayake’s group1 from Sri
Lanka reported that pralidoxime was of no
clinical benefit and should not be used.
Trials against oximes:
Vellore RCT 1: low dose Vs high dose2:
The authors argued that ‘high-dose’
pralidoxime was “associated with a worse
outcome” and stated that pralidoxime has “no
role in the routine management of patients with
OP poisoning”.
Limitation: There was no untreated control
group. This study was criticized for the
methodology.
Vellore RCT 2: high dose Vs placebo3:
The authors concluded that PAM “has no
role in the management of patients with
organophosphrous poisoning and that it “Does
more harm than good”.
Limitation: the studies did not evaluate the
current WHO-sponsored recommendations for
pralidoxime therapy
Iran trial4:
The authors concluded that atropine alone
should be used in the treatment of acute OP
poisoning.
Limitation: it was not a randomized trial
Eddleston RCT: high dose Vs saline 5:
There is no benefit from the
administration of the WHO’s recommended
regimen of pralidoxime chloride to patients with
symptomatic OP insecticide poisoning.
Trials for oximes:
Prof. Shiva Kumar trial 6:
The author concluded that patients on
high dose P2AM had better survival compared
to those on low dose P2AM. Limitation: There
was no untreated control group.
Kirti S Pawar trial 7:
Patient received high-dose regimen of
pralidoxime (infusion of 1 g/h for 48 h) after a
2 g loading dose to reduce the morbidity and
mortality in moderately severe cases of acute OP
poisoning.
Reasons for the discrepancy
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What current evidence says?
Thus, use of oximes in OP poisoning
remains conflicting and controversial. From the
randomized controlled trials, it appears that
Oximes have no effect in moderate and severe
poisoning, and do more harm than good. The
treatment options are anticholinergic drugs and
assisted ventilation, which is often required.
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Our experiences:
We have gone through several phases in
our hospital from aggressive high dose oxime
therapy to nothing at all. We couldn’t see any
difference that was worth noticing. We have
stopped using oximes for the treatment of acute
poisoning with organophosphrous pesticides. With
improved standard of care in the medical
intensive care unit, we are able to decline the
mortality to less than two percent.
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Review Article
Hypertension in Diabetes Is Blood Pressure Control more
important than Glycemic Control?
K.Raghavan
It is a well known and well established
fact that the incidence of hypertension is upto
twice as common in the diabetic as in the general
population. About a third of Type I and almost
half the Type II diabetes patients would need
antihypertensive medication; even more
significant is the fact that hypertension is
present in 20 – 40% of patients with IGT. “Risk
reduction by optional BP control is greater in
diabetic than in non-diabetic individuals”. From
the MRFIT trial it is evident that the desirable
BP in diabetics is < 130/85 mm Hg. And <125/80
mm Hg in those with Nephropathy. Both
microvascular and macrovascular complications
can be prevented if the target BP is consistently
maintained.
THE EFFECTIVENESS OF BLOOD
PRESSURE – LOWERING IN DIABETES:
Lessons from recent trials: “The
Hypertension optional treatment (HOT) study”:
In all 18790 patients were randomly assigned to
one of three blood pressure targets (<90, <85 and
<80 mm Hg.) Within the HOT study there was
a large cohort (8%, 1501) of people with diabetes,
almost all Type 2 diabetes. In this population
there was a significant trend towards greater
benefit, the lower the target (and achieved) blood
pressure. The risk of CV event was halved when
the target diastolic BP was <80 mm Hg.
In the Systolic Hypertension – Europe
study (Syst – Eur) key data emerged about the
safety and efficacy of treating Isolated Systolic
hypertention in elderly people with Type 2
diabetes. Of the 4203 patients in the Syst Eur
study there were 492 hypertensive patients
(8.6%) with diabetes. In this diabetic cohort
treatment of hypertension was associated with an
astounding benefit in terms of cardiovasular risk
reduction and reduced mortality, much greater
than that observed in non-diabetic patients.
In the UKPDS, the impact of improved
blood pressure control on all diabetes – related
and points, macrovasular and microvasular, was
remarkable. The reduction in diabetes related
end points was 24% which was twice as effective
as that achieved by efforts to improve glycemic
control. “Primary hypertension is an insulin
resistance state”
The blood vessels of a diabetic function as
though they are 10 years older than the patient.
Hence Isolated Systolic hypertension is more
common in the diabetic.
K.Raghavan
Formerly Director & Professor
Institute of Internal Medicine
Madras Medical College
Fig 1: The reduction in cardiovascular events in
patients with diabetes in the HOT study according to
the target blood pressure, The actual number of
events and achieved diastolic blood pressures are
shown below each column.
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POSSIBLE MECHANISMS OF
HYPERTENSION IN CONDITIONS OF
INSULIN RESISTANCE.
Insulin has two diametrically opposing
actions on the vascular system. It has a
vasodilator influence mediated by release of
Nitric oxide from the endothelium. It can also
“induce hypertension” by facilitating Na+ and
water reabsorption at distal renal tubule and by
stimulation of Na+ K+ ATPase which increases
intracellular Na+ Ca+ in the vascular smooth
membrane. Cytokine induced acute phase
(inflammatory) response associated with Type 2
diabetes may cause hypertension including
cytokine stimulation of ACTH and glucocorticoid
secretion and activation of sympathetic nervous
system.
“Insulin resistance is linked to
hypertension”. Approximately 50% of patients
with hypertension can be considered to have
insulin resistance and hyperinsulinemia.
How does insulin resistance cause
hypertension ?
Specifically there exists a defect in the
ability of insulin to stimulate glucose disposal by
muscle in an individual without any abnormally
in the ability of insulin to either stimulate renal
Na+ retention or enhance CNS activity. Hence
normal tissue response to insulin by the kidneys
and SNS (in individuals whose muscle and
adipose tissue are insulin resistant) helps to
explain why such individuals are at increased
risk for developing hypertension.
“Microalbuminuria, which heralds the
onset of nephropathy is defined as albaminuria
detected in the urine at levels of 30-299 mg/day”.
In Type I diabetes hypertension is most
obviously associated with diabetic nephropathy.
Blood pressure begins to rise when the
albumin excretion rate enters the
microalbuminuric range (>30 mg in 24 hrs.).
Hypertension affects virtually all patients with
persistent proteinuria. A corollary of this is that
a diabetic patient with microalbuminuria or
proteinuria cannot be labelled normotensive.
Once type 1 a type 2 diabetes patients
develop overt proteinuria (ie., nephropathy –
urinary albumin excretion > 300 mg 24 hrs) BP
increases further and the 24 hrs BP profile is
in markedly disturbed.
In the UKPDS tight BP control (mean
144/82 mm Hg) resulted in a 29% reduction in
the risk of microalbuminuria developing.
Hypertention results in progression of
microalbuminuria to overt proteinuria. Albumin
excretion can be reduced by above 50% by 2
years treatment with ACE inhibitors.
Microalbuminuria represents an increased
Fig. 2. Summary of putative pathophysiologic
mechanisms in the development of hypertension 
Fig. 3. Hypertension rises in parallel with proteinuria
in Type 1 Diabetes patients of various ages.
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permeability of the glomerulus and parallels
vascular endothelial dysfunction and predicts
development of CVD and stroke as well as
progression to diabetic nephropathy.
GENETIC PREDISPOSITION
INFLUENCES THE DEVELOPMENT OF
NEPHROPATHY.
The risk of developing nephropathy is
increased three fold if at least one parent has
hypertension – several candidate genes display
polymorphism associated with diabetic
nephropathy.
The RENAAL (reduction of end points in
NIDDM with Angiotensin II antagonist Losartan,
the IDNT (Irbesartan Diab Nephropathy trial),
IRMA 2 (Irbesartan microalbuminuria for Type
2 DM) have all shown reduction in proteinuria
and slowed the progression of renal disease. The
beneficial effects of ARB’s on nephropathy were
independent of the changes in BP.
HYPERTENSION / DIABETES & (CAD)
Effect of BP on risk of fatal coronary
artery disease is 2 to 5 times greater in diabetic
than in non-diabetic population. Hypertension
also worsens LV function. Lowering of systolic BP
by 10 – 12 mm. Hg. and diastolic BP by 5-6 mm.
Hg. confers risk reduction of 35 – 40% for stroke,
12 – 16% for CHD, within 5 years of initiating
treatment. “Appropriate combination of drugs at
lower doses has additive effects on control with
less side effects”
To achieve recommended BP goals the
majority of individuals with require treatment
with more than one drug. ≥ 3 drugs are required
in patients with diabetes and renal insufficiency.
Diabetes tends to eliminate the female advantage
women have over men as candidates for all CVD.
In both DCCT (Type 1) & UKPDS (Type
2) improved glycemic control had no significant
effect on cardiovascular outcomes. However in
UKPDS tight BP control over 9 years showed a
large reduction in risk of strokes (44%) and in
microvascular end points (retinopathy,
microalbuminuria)
Fig. 4. The prevalence of Hypertension is increased
in parents of those with proteinuria, which suggests
that genetic position may influence the development
of nephropathy
Fig. 5. Antihypertensive treatment
Fig. 6. Risk of Cardiovascular events according to
SBP & Diabetic status. Framingham Study 
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In the 10 year follow up study of patients
in the UKPDS (NEJM 2008, 369 : 565-76) the
benefits of previously improved BP control was
not sustained when between group difference the
BP were lost – it appears that good BP control
must be continued if the benefits are to be
maintained. Interestingly in case of blood sugar
control in the same study a “legacy effect” was
observe more than 10 years after the study
period; in other words individuals whose glycemic
control was strictly maintained continued to have
sustained benefits long after study period. The
benefits shown in UKPDS were corroborated in
subsequent trials such as the “Hot study”
Syst-Eur and SHEP. In the ‘Micro-Hope” study
3577 patients with Type 2 DM who were treated
with Ramipril showed a reduction of primary
combined end point of MI, Stroke and CVD
mortality by 25% and of stroke alone by 33%.
The ALLHAT, LIFE & the recent
ADVNCE have all shown similar benefits.
“Reduced Nocturnal dip”
The characteristic disturbance in 24 hours
BP regulation in Type I and Type 2 diabetes is
a reduction in the normal nocturnal dip in BP
usually associated at higher nocturnal heat rate.
The night – day BP ratio is particularly
disturbed in patients with microalbuminuria
(incipient nephropathy) and diabetes. “Target the
associated deceases like recent MI, CCF, kidney
deceases”.
Treatment strategy : What is the initial
drug choice ?
Answer : It doesn’t matter. Because
multiple medications will be required to achieve
blood pressure goals.
Although an ACE – I is reasonable.
(Robert C Stanton , Joslin Diabetes Centre)
Fig. 7. Effects of Blood Pressure Control on Mortality & Vascular events in patients with Type 2 DM.
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ECG - Section
Diagnose the ECG Abnormalities
Dr. Ulhas M. Pandurangi MD, DM
What is the diagnosis of tachycardia in the ECG?
The answer for the previous issue
(Volume 2, Issue 1, January -April 2010) is
“intermittent pre excitation with “T” wave
memory sign”
Dr. Ulhas M. Pandurangi MD, DM
Cardiac Electrophysiologist and Interventional
Cardiologist, Madras Medical Mission, Chennai,
Tamilnadu
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QUIZ
QUIZ: E.C.G. (non progression of R wave)
(a) What is this condition which led to Non-progression of R waves in precordial leads?
(b) What other special leads would help to confirm it?
P.Alagia Nambi, Consultant Diabelogist
Sri Gokulam Hospital
3/60, Mayyanur Road
Salem, 636 004, T.N.
email: alagia_nambi@yahoo.co.in
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Review Article
Saxagliptin: A New DPP- 4 Inhibitor in Type 2 Diabetes
DR. Vijay Viswanathan., MD., Ph.D., FRCP (London), FRCP (Glasgow)
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Introduction
Diabetes mellitus is a group of chronic
metabolic diseases characterized by
hyperglycaemia [1]. Approximately 90% of these
cases are type 2 diabetes[2] which is the result
of underlying insulin resistance and a progressive
insulin secretory defect[1]. There is a wide range
of antidiabetic drugs currently available in the
market, but the success of many of these agents
is undermined by safety and tolerability issues,
barriers to adherence and waning efficacy as the
disease progresses. The newest line of treatments
against type 2 diabetes, the so-called
incretin-based therapies, including the dipeptidyl
peptidase 4 (DPP-4) inhibitors was designed to
address these issues. 
Saxagliptin (Onglyza) is one such DPP-4
inhibitor that has recently been approved for use
in patients with type 2 diabetes[3]. Saxagliptin is
approved in India, as monotherapy and
combination therapy, as “an adjunct to diet and
exercise to improve glycemic control in adults
with type 2 diabetes”[3]. It has not been evaluated
as an adjunct to insulin[3]) and is not indicated
for type 1 diabetes nor diabetic ketoacidosis[3].
This article reviews the pharmacological
properties, clinical efficacy and tolerability of oral
saxagliptin in adult patients with type 2 diabetes.
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Pharmacodynamic Profile
The incretin pathway plays a key role in
the pathogenesis of type 2 diabetes. Incretin
hormones are produced in the gastrointestinal
tract following food intake to exert
glucoregulatory actions, the so-called incretin
effect[6,7]). The incretin effect works through the
incretin hormones glucagon-like peptide-1
(GLP-1) and glucose dependent insulinotropic
polypeptide (GIP) which stimulate insulin
secretion regulate gastric clearance and inhibit
glucose production by the liver. These hormones
are normally degraded and inactivated by the
serine protease enzyme DPP-4.
In patients with type 2 diabetes, the
incretin effect is significantly diminished due to
dysfunction in the secretion, metabolism and
responsiveness of the incretin hormones [7]. The
class of drugs called DPP-4 inhibitors is designed
to counteract DPP-4’s degradation effects. One of
these drugs is saxagliptin, a selective potent
inhibitor of the DPP-4 enzyme system. Its
mechanism of action is to exert long-lasting yet
reversible inhibition of the DPP-4, thereby
slowing down the inactivation of the incretin
hormones and enhancing the incretin effect. The
chemical structure of saxagliptin is shown in
Figure 1 and its chemical development has been
described in several papers[8-10].
Fig 1. Chemical Structure of Saxagliptin
Saxagliptin is a potent, selective,
reversible inhibitor of the DPP-4 enzyme.[5] It is
10-fold more potent than vildagliptin or
sitagliptin, with an inhibitory constant (Ki) of 1.3
nmol/L for DPP-4 at 37°C (Ki = 13 and 18 nmol/L
for vildagliptin and sitagliptin).[13]. The active
metabolite of saxagliptin, M2 (BMS-510849), is
2-fold less potent than saxagliptin, with a Ki of
2.6 nmol/L. [5]
Saxagliptin dosages of 2.5–400 mg once
daily for 14 days inhibited DPP-4 enzymatic
activity in a dose-dependant manner in patients
with type 2 diabetes and in healthy volunteers,
with the inhibition profile at these dosages being
consistent with once-daily administration [4].
Saxagliptin and its active metabolite are more
selective for the inhibition of DPP-4 than DPP-8
(400- and 950- fold) or DPP-9 (75- and 160-fold)
enzymes or a large panel of other proteases
(>4000-fold) [5]. It has been suggested that once
bound, saxagliptin and its active metabolite
would continue to inhibit DPP-4 during rapid
increases of substrate in vivo, owing to their slow
dissociation from the enzyme[5]. Saxagliptin
2.5–400 mg once daily increased postprandial
plasma intact GLP-1 levels by 1.5- to 3-fold after
breakfast, lunch and dinner on day 13 (in
patients with type 2 diabetes) or day 14 (in
healthy volunteers) compared with placebo, with
no apparent dose-relationship being observed[4].
Saxagliptin as monotherapy or in combination
with other antihyperglycaemic agents improved
glycaemic control and generally improved β-cell
function in large clinical trials of up to 24 weeks’
duration in patients with type 2 diabetes.
Saxagliptin (2.5–400 mg/day for 14 days) or its
active metabolite did not prolong the corrected
QT interval in patients with type 2 diabetes or
healthy volunteers [4].
Pharmacokinetic Profile
Special Populations
In patients with mild renal impairment
(creatinine clearance [CLCR] 50–80 mL/min
[3–4.8 L/h]), the AUC from time zero to infinity
(AUC∞) of saxagliptin and M2 were 1.2- and 1.7-
fold higher than in patients with normal renal
function (CLCR > 80mL/min [>4.8 L/h]); however,
this increase was not considered clinically
relevant and no dosage adjustment is
recommended [3,15]. In patients with moderate
(CLCR 30–50 mL/min [1.8–3.0 L/h]) or severe
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(CLCR <30mL/min [<1.8 L/h]) renal impairment,
the AUC∞ of saxagliptin and M2 were up to 2.1-
and 4.5-fold higher than in patients with normal
renal function; therefore, dosage reduction is
recommended in these patients. In eight patients
with end-stage renal disease, 23% of the
saxagliptin dose was eliminated during a 4-hour
haemodialysis session[3,15]. No dosage adjustments
are required in patients with hepatic impairment
(Child-Pugh classes A, B or C) as, overall, the
pharmacokinetics of saxagliptin differed by less
than 2-fold between individuals with mild to
severe hepatic impairment and healthy
volunteers, and were not considered clinically
relevant[3,17]. The pharmacokinetics of saxagliptin
are generally not affected by sex or age in
healthy volunteers and no dosage adjustments
are considered necessary[3,18]. As the metabolism
of saxagliptin is mediated by CYP3A4 and
CYP3A5 isoenzymes, strong inhibitors and
inducers of these isoenzymes will alter the
pharmacokinetics of saxagliptin[3]. Studies have
investigated potential drug-drug interactions of
saxagliptin in healthy subjects and came to the
conclusion that the potential for clinically
meaningful interactions between saxagliptin and
metformin[12], glibenclamide [13], pioglitazone[14],
digoxin[15], omeprazole [16] or famotidine [16] is
low.
Monotherapy
Saxagliptin has been approved by the U.S.
Food and Drug Administration (FDA) and Drug
Controller General of India (DCGI) as an adjunct
to exercise and diet in the treatment of type 2
diabetes. It is administered orally once daily with
or without food [3]. Several studies reported on
the efficacy and safety of saxagliptin
monotherapy. Rosenstock et al evaluated
saxagliptin as monotherapy for type 2 diabetes
drug naive patients in several studies, two of
which have been published in peer-reviewed
journals [19,20]. In one study, following
administration of saxagliptin at 2.5, 5 and 10 mg
once daily for 24 weeks, significant and clinically
meaningful reductions in HbA1C (–0.43, – 0.46
and –0.54%, respectively) and FPG-AUC from
baseline were observed [19]. No weight gain or
increased incidence of hypoglycemia was
reported. The number of patients that achieved
glycemic goals was higher in groups administered
with saxagliptin (35, 38, 41%, for 2.5, 5 and 10
mg, respectively), compared to placebo (24%). In
another similar study with higher saxagliptin
doses (2.5-40 mg), a similar trend in
improvements in glycemic parameters was
observed [20].
Add-on therapy
Several clinical studies have investigated
the efficacy of saxagliptin as add-on therapy to
some of the most commonly used antidiabetic
drugs. The changes from baseline in HbA1C
levels and the proportion of patients reaching
glycemic targets in these comparative studies are
shown in Table I [21-25]. These studies
demonstrated the efficiency of saxagliptin as
add-on therapy. Thus, it has been approved by
the European Medicines Agency as an add-on
combination therapy to one of existing
glucoregulatory drugs (metformin, a sulfonylurea,
and a thiazolidinedione) in patients who are not
able to achieve glycemic goals with their existing
therapy plus diet and exercise [3]. In Canada,
saxagliptin has been approved as adjunct to
metformin or a sulfonylurea when these drugs
alone, with diet and exercise do not provide
adequate glycemic control [3].
Saxagliptin and metformin
Metformin is the most commonly
prescribed drug for first line treatment of type
2 diabetes. However, with the progression of the
disease, increasing insulin resistance and β-cell
dysfunction, metformin becomes inadequate in
controlling glucose levels. It is also associated
with adverse events that include hypoglycemia,
weight gain and gastrointestinal intolerance [26].
Several studies observed improved glycemic
control when saxagliptin is used in combination
with metformin, either as add-on initial therapy
or as add-on to ongoing metformin therapy
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[21,22,24,27-28]. Two of these studies have been
published in peer-reviewed journals. The efficacy
and safety of saxagliptin plus metformin as
initial combination therapy vs. monotherapy of
either drug was investigated by Jadzinsky et
al[21]. The results showed that the combination
therapy was significantly better in lowering
HbA1C levels compared to either saxagliptin or
metformin as stand-alone agents. Other glycemic
parameters (FPG and PPG-AUC) also
significantly improved with the combination
therapy (Table I). In another study, the efficacy
of add-on saxagliptin (2.5, 5 and 10 mg) plus
metformin combination therapy vs. metformin
monotherapy was compared[22]. The results
showed that a once-daily saxagliptin as add-on
to ongoing metformin therapy significantly
improved glycemic control (Table I).
Hypoglycemia
The occurrence of hypoglycemic events is
a major hindrance to type 2 diabetes therapy
adherence. Many of the existing antidiabetic
agents are associated with increased incidence of
hypoglycemia. As part of safety evaluation of
saxagliptin, clinical studies reported the
frequency of hypoglycemic events. Six published
papers reported low incidence of hypoglycemia
associated with saxagliptin as mono- or add-on
therapy [19-23,25]. Rosenstock et al[20] reported
hypoglycemia incidences to be similar between
saxagliptin and placebo.
Table 2: Adverse events reported in studies
Reported in published studies on saxagliptin
 (frequency of = 5)
Reported adverse event Reported by
Dyspepsia [22]
Headache [21,22,23,25]
Influenza [22,23]
Nasopharyngitis [21,22,23,25]
Pain in extremity [22,23]
Peripheral edema [25]
Upper respiratory tract infection [22,23,25]
Urinary tract infection [22,23,25]
Incidences of hypoglycemia in studies on
saxagliptin as add-on therapy are shown in Table
I. In an abstract, Chen et al[30] presented
hypoglycemic incidence data from six double-blind
randomized trials comparing saxagliptin as
monotherapy vs. as add-on therapy to metformin,
TZD or a sulfonylurea. Results showed that
hypoglycemic events were infrequent, with
similar incidence rates in all groups.
Weight gain
Some antidiabetic drugs are associated
with weight increase. Published data indicate
that saxagliptin is generally weight-neutral, i.e.
its use does not result in weight increase or
reduction. Two published studies reported slight
weight increases[23,25] and another 2 reported
weight losses [21,22] but these changes in weight
from baseline were not considered to be clinically
significant.
Cardiovascular Events
Saxagliptin as monotherapy or in
combination with other oral antihyperglycaemic
agents was not associated with an increased risk
of cardiovascular events, according to pooled data
from eight clinical trials[31]. In these trials, the
overall exposure to saxagliptin was 3758
patient-years and to the comparators (placebo,
metformin or glibenclamide) was 1293
patient-years; 81% of patients had at least one
cardiovascular risk factor in addition to diabetes
(including hypertension [52%], dyslipidaemia
[44%] or history of smoking [39%]) and 12% had
prior history of cardiovascular disease[31]. In this
analysis, acute cardiovascular events occurred in
1.1% of patients in the saxagliptin group
compared with 1.8% of patients in the
comparator group (hazard ratio [HR] 0.59 [95%
CI 0.35, 1.0]; n = 3356 and 1251); few patients
receiving saxagliptin had major adverse
cardiovascular events (0.7% vs 1.4% in the
comparator group; HR 0.44 [95% CI 0.24, 0.82])
[31]. The incidences of all-cause death (0.3% vs
1.0% comparators) and cardiovascular death
(0.2% vs 0.8%) were also low in patients receiving
saxagliptin therapy (Table 3) [31].
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β-Cell function
As type 2 diabetes progresses, the
functioning of the β-cells of the pancreas
responsible for insulin secretion also
progressively declines, undermining the efficacy
of antidiabetic drugs. One hypothesis regarding
the mechanism of action of saxagliptin is the
improvement of β-cell response. A randomized
double-blind placebo controlled study investigated
the effect of saxagliptin monotherapy on β-cell
function in drug-naive patients32]. Saxagliptin
was administered through an intravenous
hyperglycemic clamp. The primary endpoint was
the change in total insulin secretion from
baseline in the fasting state; secondary end point
the change in postprandial insulin secretion.
Following a 12-week saxagliptin treatment,
fasting and postprandial insulin levels relative to
baseline were significantly improved and
postprandial glucagon concentration lower
compared to those who received placebo. The
results suggest a positive effect of saxagliptin on
the pancreatic β-cells. Hollander et al[25]
evaluated β-cell functioning in a randomized,
placebo-controlled study using HOMA-2β
measurements. Following 24 weeks of saxagliptin
plus TZD treatment, increases in HOMA-2β were
observed, indicative of improved β-cell function.
Two other published studies reported significant
increases in HOMA-2β (Table I) following
saxagliptin treatment[23,24]. In addition,
significant improvements in insulinogenic index,
which is a measure of early insulin response to
a glucose load, were also observed.
Dosage and Administration
In patients with type 2 diabetes, the
recommended dosage of saxagliptin is 2.5 mg or
5 mg once daily administered orally without
regard for food[3]. In patients with moderate or
severe renal impairment (CLCR ≤ 50mL/min [≤
3L/h]), and in patients with end-stage renal
disease requiring haemodialysis, the dosage of
saxagliptin should be adjusted to 2.5 mg/day to
achieve plasma exposures of saxagliptin and M2
that are similar to those in patients with normal
renal function; no dosage adjustment is required
in patients with mild renal impairment[3].
Saxagliptin dosage should also be adjusted to 2.5
mg/day when the drug is co-administered with
strong CYP3A4/5 inhibitors (e.g. ketoconazole,
atazanavir or clarithromycin). Saxagliptin should
not be used for the treatment of type 1 diabetes
or diabetic ketoacidosis and the drug has not
been studied in combination with insulin[3]. Local
prescribing information should be consulted for
comprehensive dosage and administration
guidelines, contraindications, precautions and
drug interactions.
Conclusion
Most of the clinical studies on saxagliptin
reported a positive efficacy profile as mono- or
add-on therapy in improving key glycemic
parameters and in attaining glycemic targets.
These studies also reported a good saxagliptin
tolerability profile, with little indication of CV
effects, and with the additional benefit of having
no significant effect on weight or incidence of
hypoglycemia. These improvements are expected
to improve adherence to therapies and help
achieve long-lasting glycemic control in patients
with type 2 diabetes. Saxagliptin, therefore, is a
welcome addition to the wide range of
antidiabetic drugs currently available and may be
a potent weapon in the fight against the type 2
diabetes epidemic. However, like all new drugs,
the long-term safety and efficacy of saxagliptin
needs to be established by post-marketing data.
Saxagliptin: Current Status
In India, saxagliptin is indicated as an
adjunct to diet and exercise (monotherapy and
combination therapy) to improve glycaemic
control in patients with type 2 diabetes. Oral
saxagliptin as monotherapy or in combination
with other antihyperglycaemic agents improved
glycaemic control and was generally well
tolerated in several large, well designed trials of
up to 24 weeks duration and in a long-term
extension study in adult patients with type 2
diabetes.
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